PMC:7242013 / 13703-13986 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T44","span":{"begin":141,"end":149},"obj":"Body_part"}],"attributes":[{"id":"A44","pred":"fma_id","subj":"T44","obj":"http://purl.org/sig/ont/fma/fma82768"}],"text":"It is uncertain whether HCC treatment should be deferred or started as usual in patients with COVID‐19 with newly diagnosed HCC, and whether tyrosine kinase inhibitors (TKIs) or checkpoint inhibitors should be stopped in patients with COVID‐19 who are already receiving such therapy."}

{"project":"LitCovid-PubTator","denotations":[{"id":"420","span":{"begin":124,"end":127},"obj":"Gene"},{"id":"421","span":{"begin":24,"end":27},"obj":"Gene"},{"id":"425","span":{"begin":80,"end":88},"obj":"Species"},{"id":"426","span":{"begin":221,"end":229},"obj":"Species"},{"id":"427","span":{"begin":141,"end":156},"obj":"Gene"},{"id":"428","span":{"begin":94,"end":102},"obj":"Disease"},{"id":"429","span":{"begin":235,"end":243},"obj":"Disease"}],"attributes":[{"id":"A420","pred":"tao:has_database_id","subj":"420","obj":"Gene:619501"},{"id":"A421","pred":"tao:has_database_id","subj":"421","obj":"Gene:619501"},{"id":"A425","pred":"tao:has_database_id","subj":"425","obj":"Tax:9606"},{"id":"A426","pred":"tao:has_database_id","subj":"426","obj":"Tax:9606"},{"id":"A427","pred":"tao:has_database_id","subj":"427","obj":"Gene:7294"},{"id":"A428","pred":"tao:has_database_id","subj":"428","obj":"MESH:C000657245"},{"id":"A429","pred":"tao:has_database_id","subj":"429","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"It is uncertain whether HCC treatment should be deferred or started as usual in patients with COVID‐19 with newly diagnosed HCC, and whether tyrosine kinase inhibitors (TKIs) or checkpoint inhibitors should be stopped in patients with COVID‐19 who are already receiving such therapy."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T171","span":{"begin":24,"end":27},"obj":"Disease"},{"id":"T172","span":{"begin":94,"end":102},"obj":"Disease"},{"id":"T173","span":{"begin":124,"end":127},"obj":"Disease"},{"id":"T174","span":{"begin":235,"end":243},"obj":"Disease"}],"attributes":[{"id":"A171","pred":"mondo_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/MONDO_0007256"},{"id":"A172","pred":"mondo_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A173","pred":"mondo_id","subj":"T173","obj":"http://purl.obolibrary.org/obo/MONDO_0007256"},{"id":"A174","pred":"mondo_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"It is uncertain whether HCC treatment should be deferred or started as usual in patients with COVID‐19 with newly diagnosed HCC, and whether tyrosine kinase inhibitors (TKIs) or checkpoint inhibitors should be stopped in patients with COVID‐19 who are already receiving such therapy."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T56","span":{"begin":141,"end":167},"obj":"Chemical"},{"id":"T57","span":{"begin":141,"end":149},"obj":"Chemical"},{"id":"T58","span":{"begin":157,"end":167},"obj":"Chemical"},{"id":"T59","span":{"begin":189,"end":199},"obj":"Chemical"}],"attributes":[{"id":"A56","pred":"chebi_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/CHEBI_38637"},{"id":"A57","pred":"chebi_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/CHEBI_18186"},{"id":"A58","pred":"chebi_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A59","pred":"chebi_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"It is uncertain whether HCC treatment should be deferred or started as usual in patients with COVID‐19 with newly diagnosed HCC, and whether tyrosine kinase inhibitors (TKIs) or checkpoint inhibitors should be stopped in patients with COVID‐19 who are already receiving such therapy."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T5","span":{"begin":150,"end":167},"obj":"http://purl.obolibrary.org/obo/GO_0033673"}],"text":"It is uncertain whether HCC treatment should be deferred or started as usual in patients with COVID‐19 with newly diagnosed HCC, and whether tyrosine kinase inhibitors (TKIs) or checkpoint inhibitors should be stopped in patients with COVID‐19 who are already receiving such therapy."}

{"project":"LitCovid-sentences","denotations":[{"id":"T150","span":{"begin":0,"end":283},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"It is uncertain whether HCC treatment should be deferred or started as usual in patients with COVID‐19 with newly diagnosed HCC, and whether tyrosine kinase inhibitors (TKIs) or checkpoint inhibitors should be stopped in patients with COVID‐19 who are already receiving such therapy."}